Intended for U.S. scientific audiences only.
BMS at #EULAR2020
Pursuing the Advancement of Precision Medicines Through Biomarker Science in Immune-Mediated Diseases for Patients with Unmet Needs
t the European League Against Rheumatism (EULAR) 2020 Congress, we’re presenting 27 Bristol Myers Squibb-sponsored abstracts, underscoring our commitment to advancing precision medicine and developing more targeted approaches to treating immune-mediated diseases where treatment options are limited or medical unmet needs still exist. The presented data include clinical, real-world and biomarker studies that focus on furthering precision medicine in rheumatoid arthritis as well as other conditions, including juvenile idiopathic arthritis.
Check out the latest educational resources below: